ロード中...
Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
In this open-label study, we evaluated the effect of upfront macitentan and riociguat combination in newly diagnosed pulmonary arterial hypertension (PAH) patients. In 15 consecutive PAH patients, we collected clinical and hemodynamic data at baseline, visit 1 (median 4 months) and visit 2 (median 1...
保存先:
| 出版年: | Pulm Circ |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6378454/ https://ncbi.nlm.nih.gov/pubmed/30638432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894019826944 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|